MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. Background: For patients with breast cancer undergoing neoadjuvant systemic treatment (NST) the optimal timing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results